Heron Therapeutics posts $34.7M Q1 revenue, reaffirms $173–$183M 2026 guidance amid strong Acute Care growth

Heron Therapeutics reported $34.7 million in net revenue for Q1 2026, driven by a 32% year-over-year increase in its Acute Care franchise, including strong sales of ZYNRELEF and APONVIE. Despite a 26% decline in Oncology revenue, the company reaffirmed its full-year 2026 guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA. Key growth drivers include commercial expansion, reimbursement improvements, and new sales initiatives planned for the Acute Care franchise. Heron also settled patent litigation related to CINVANTI, supporting stability in its Oncology segment moving forward.